DefiniGEN Ltd

DefiniGEN Ltd

DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology.

Telephone: +44 (0)1223 497 113
Address: Maia Building, Babraham Research Campus, Babraham
Postcode: CB22 3AT
Country: United Kingdom
Website: http://www.definigen.com
Membership type:Corporate 6-20 (£250+VAT pa)

Definigen provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes. The Company’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.

Definigen has utilised the OptiDIFF platform to produce validated libraries of disease modelled human liver cells for a range of Inherited Metabolic Diseases (IMDs). The phenotype and pathology of the diseases has been confirmed in the cells and the resulting products are available for utilisation in drug discovery lead optimization studies.

Professor Sir John Savill

DefiniGEN strengthens Board with appointment of Professor Sir John Savill

DefiniGEN, the world leader in human iPSC differentiation and disease modelling, announces the appointment of Professor Sir John Savill as a Non-Executive Director of the Board.

12 September 2018Read in full

DefiniGEN licenses cholangiocyte stem cell technology from Cambridge Enterprise

DefiniGEN licenses cholangiocyte stem cell technology from Cambridge Enterprise

DefiniGEN, a leading provider of stem cell products and services, today announced that it has strengthened its IP portfolio with a licence for cutting-edge cholangiocyte liver technology from Cambridge Enterprise, the commercialisation arm of the University of Cambridge.

27 April 2017Read in full

Dr Marcus Yeo, CEO of DefiniGEN

DefiniGEN raises £1.5M in follow-on funding

DefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The investment will be used to fund the commercial launch of new pancreatic and lung stem cell products for drug discovery and regenerative medicine.

23 May 2016Read in full

 Dr Marcus Yeo, CEO DefiniGEN.

DefiniGEN licenses lung stem cell technology from University of Cambridge

DefiniGEN Ltd, a leading provider of stem cell life science products and services, today announced that it has strengthened its IP portfolio with a licence for cutting edge lung stem cell technology from the University of Cambridge. The technology will be used by DefiniGEN to develop new, optimised cell products and services for drug discovery and the study of lung diseases, including cystic fibrosis.

11 August 2015Read in full

DefiniGEN joins European Bank for Induced Pluripotent Stem Cells (EBiSC) Consortium

EFPIA pharmaceutical companies, SMEs, and academia join together in an IMI supported public-private partnership project to establish the leading facility for the storage and distribution of induced pluripotent stem (iPS) cells in Europe.

27 August 2014Read in full

Dr Marcus Yeo, CEO DefiniGEN.

DefiniGEN announces closing of £2.3 million Series A fundraising

DefiniGEN Ltd, a leading provider of stem cell life science products and services, today announced the final closing of its Series A funding round. The latest £1 million ($1.6 million) placement for ordinary shares brings to a close a cumulative total for the round of £2.28 million ($3.83 million), which will support the international expansion of the business and the commercial launch of new products.

2 June 2014Read in full

Cambridge SEIS Fund makes its first investments

The University of Cambridge Enterprise Fund has made its first investments in three companies: Cambridge CMOS Sensors, Inotec AMD and DefiniGEN.

16 November 2012Read in full

The role of stem cells in developing new drugs

Cambridge team which developed method to generate liver cells from skin cells has formed a new company to supply stem cell products to the drug discovery and regenerative medicine sectors

30 October 2012Read in full